Adrian Senderowicz
Direktor/Vorstandsmitglied bei PUMA BIOTECHNOLOGY, INC.
Vermögen: 131 760 $ am 30.04.2024
Profil
Adrian M.
Senderowicz is currently serving as an Independent Director at Puma Biotechnology, Inc., a Non-Executive Director at Oncoinvent AS, and a Director at Step Pharma SAS.
He previously worked as a Senior Medical Director at AstraZeneca PLC, Vice President of Global Regulatory Oncology at Sanofi, Head of Prostate Cancer Clinic at National Institutes of Health, Clinical Team Leader at US Food & Drug Administration, Chief Medical Officer & VP of Medical Development at Tokai Pharmaceuticals, Inc., Chief Medical Officer & Senior Vice President at Cerulean Pharma, Inc., Chief Medical Officer & Senior Vice President at Constellation Pharmaceuticals, Inc., Chief Medical Officer & SVP of Regulatory Affairs at Ignyta, Inc., and Chief Medical Officer & Senior Vice President at Daré Bioscience, Inc. He holds a doctorate degree from Universidad de Buenos Aires.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PUMA BIOTECHNOLOGY, INC.
0,06% | 22.04.2024 | 27 000 ( 0,06% ) | 131 760 $ | 30.04.2024 |
Aktive Positionen von Adrian Senderowicz
| Unternehmen | Position | Beginn |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Direktor/Vorstandsmitglied | 11.08.2015 |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Direktor/Vorstandsmitglied | 06.10.2021 |
Oncoinvent AS
 Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Direktor/Vorstandsmitglied | 04.02.2022 |
Ehemalige bekannte Positionen von Adrian Senderowicz
| Unternehmen | Position | Ende |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 22.06.2020 |
Cerulean Pharma, Inc.
 Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Technik-/Wissenschafts-/F&E-Leiter | 15.06.2017 |
| DARÉ BIOSCIENCE, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2017 |
| IGNYTA INC | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2015 |
| SANOFI | Corporate Officer/Principal | 01.04.2014 |
Ausbildung von Adrian Senderowicz
| Universidad de Buenos Aires | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| PUMA BIOTECHNOLOGY, INC. | Health Technology |
| SANOFI | Commercial Services |
| DARÉ BIOSCIENCE, INC. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Tokai Pharmaceuticals, Inc.
 Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Health Technology |
US Food & Drug Administration
 US Food & Drug Administration General GovernmentGovernment US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD. | Government |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Ignyta, Inc.
 Ignyta, Inc. BiotechnologyHealth Technology Ignyta, Inc. operates as a medicine biotechnology company. The firm engages in the discovering, acquiring, developing and commercializing targeted new drugs for cancer patients. The company was founded by Jonathan E. Lim on September 13, 2011 and is headquartered in South San Francisco, CA. | Health Technology |
Cerulean Pharma, Inc.
Cerulean Pharma, Inc. Pharmaceuticals: MajorHealth Technology Cerulean Pharma, Inc. is a clinical-stage, oncology-focused company, which provides proprietary Dynamic Tumor Targeting Platform to develop differentiated therapies. It specializes in the design and development of nanopharmaceuticals. Cerulean's nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules. The company was founded by Alan L. Crane and Ram Sasisekharn on November 28, 2005 and is headquartered in Waltham, MA. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Step Pharma SAS
Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Health Technology |
Oncoinvent AS
Oncoinvent AS Pharmaceuticals: MajorHealth Technology Oncoinvent AS develops antibody based therapeutic molecules for cancer treatment. It offers antigen-binding domains that develops coupling to nanoparticles and drug candidates. The firm provides antibodies (the OI-antibodies) with clinical relevant binding-specificity and also designs molecules and drug conjugates for treatment of specific cancer diseases. The company was founded by Tina Bjornlund Bonsdorff, ?yvind Sverre Bruland, Roy Hartvig Larsen, and Thora Johanna Jonasdottir in 2010 and is headquartered in Oslo, Norway. | Health Technology |
